Compare PAC & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAC | BMRN |
|---|---|---|
| Founded | 1998 | 1996 |
| Country | Mexico | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.9B | 12.3B |
| IPO Year | 2006 | 1999 |
| Metric | PAC | BMRN |
|---|---|---|
| Price | $229.03 | $62.05 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 28 |
| Target Price | ★ $246.20 | $90.30 |
| AVG Volume (30 Days) | 96.7K | ★ 2.0M |
| Earning Date | 10-19-2026 | 11-02-2026 |
| Dividend Yield | ★ 4.38% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.14 |
| Revenue | N/A | ★ $1,313,646,000.00 |
| Revenue This Year | $43.10 | $20.01 |
| Revenue Next Year | $9.94 | $14.75 |
| P/E Ratio | ★ $27.29 | $426.71 |
| Revenue Growth | N/A | ★ 17.62 |
| 52 Week Low | $192.65 | $49.26 |
| 52 Week High | $300.41 | $70.98 |
| Indicator | PAC | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 47.81 | 65.45 |
| Support Level | $222.37 | $58.03 |
| Resistance Level | $254.69 | $66.95 |
| Average True Range (ATR) | 6.75 | 2.13 |
| MACD | -2.27 | 0.68 |
| Stochastic Oscillator | 7.78 | 83.75 |
Grupo Aeroportuario del Pacifico SAB de CV is engaged in the operation, maintenance, and development of 12 international airports in Mexico and two international airports in Jamaica. The company's segment includes Guadalajara, Tijuana, Puerto Vallarta, San Jose del Cabo, Montego Bay, Hermosillo, and Guanajuato airports. It generates the maximum revenue from the Guadalajara segment.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.